Certain anti-diabetic drugs like pioglitazone (via peroxisome proliferator-activated receptor γ activation) and liraglutide (via glucagon-like peptide 1 receptor activation) have been shown to upregulate ACE2 in animal models [11, 12]; however, the current evidence does not support any change in the ongoing medications [13].